Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Saved in:
| Title: | Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. |
|---|---|
| Authors: | Zamulko O; Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio., Karivedu V; Division of Hematology/Oncology, Duke University Medical Center, Durham, North Carolina., Riaz MK; St. Elizabeth Healthcare, Edgewood, Kentucky., Monroe I; University of Cincinnati Cancer Center, Cincinnati, Ohio., Romano A; University of Cincinnati Cancer Center, Cincinnati, Ohio., Mulanda R; University of Cincinnati Cancer Center, Cincinnati, Ohio., Kurtzweil N; University of Cincinnati Cancer Center, Cincinnati, Ohio., Forsythe A; University of Cincinnati Cancer Center, Cincinnati, Ohio., Allen CL; University of Cincinnati Cancer Center, Cincinnati, Ohio., Harun N; Cytel, Cincinnati, Ohio., Pan J; Biostatistics and Informatics Shared Resource, University of Cincinnati Cancer Center, Cincinnati, Ohio.; Cancer Data Science Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.; Department of Biostatistics, Health Informatics and Data Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio., Rai S; Biostatistics and Informatics Shared Resource, University of Cincinnati Cancer Center, Cincinnati, Ohio.; Cancer Data Science Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.; Department of Biostatistics, Health Informatics and Data Sciences, University of Cincinnati College of Medicine, Cincinnati, Ohio., El-Gamal D; Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio., Wise-Draper TM; Division of Hematology Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio. |
| Source: | Cancer research communications [Cancer Res Commun] 2025 Jun 01; Vol. 5 (6), pp. 939-944. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
